The new technology from University of Houston could make any mask more resistant to viruses. Photo courtesy of Seamus Curran/Integricote

The start of 2020, though most didn't know it at the time, meant a huge change to society. Though coronavirus didn't yet seem to be an issue for the United States, the world was entering into a new normal where wearing face masks in public is common and necessary to prevent the spread of COVID-19.

"We left normal in December," says Seamus Curran, a professor of physics at the University of Houston, "and, when everyone was planning their New Year's resolutions, little did we know that the old normal of before is gone. None of us saw that life passing away — and it was taken away by a bug 1,000 times smaller than lice. And like lice, it's going to be with us for a long time."

To that end, Curran, who is well-known for his work commercializing nanotechnologies, is pulling from his past to deal with a future demand. The professor is using a hydrophobic coating he developed nearly 10 years ago to improve the ability of surgical masks to protect against transmission of the virus.

It's no secret that good face masks are a dire, worldwide need. But Curran notes that standard masks are "somewhat porous, and especially if they get wet, they can allow the virus to penetrate." People infected with the virus, he adds, could spread it even through a mask, while people who aren't sick could still become infected, despite wearing a less-protective mask.

Curran calls N95 masks, "the gold standard, able to filter very small particles and offering better protection than standard surgical masks." But he notes that they are hard to manufacture, and global demand is for tens of millions of items. His work will make masks impervious to water, thus improving protection, he explains.

That means those who already own masks are in luck: Curran's team is planning to sell spray for the hydrophobic coatings so that people can apply it themselves at home or at work. "However, it's cheaper and far more effective to be able to apply it in large batch quantities that manufacturers can do," Curran adds.

The globally minded Curran has only one local requirement: "We will only sell to U.S. manufacturers that manufacture here in the U.S. It's not a limiting factor and may change in the future, but right now, I have to deal with my community here in Houston, Texas, and the U.S. It has to be my priority."

University of Houston's Dr. Seamus Curran. Photo courtesy of University of Houston

Curran and his team are working though the process to make sure their coatings are compliant with all federal rules. "Sometimes, this is making sure your materials are registered and allowed," he says. "Sometimes it's making sure the products follow relevant EPA and FDA guidelines. However, we are very close, as in weeks, and not some arbitrary academic timeline in the distant future."

He first launched a nanotechnology business in 2013, according to UH. His company, Integricote, based at the UH Technology Bridge, focuses on manufacturing sealers for masonry, wood, and concrete. The professor has developed nanotech coatings for fabrics since 2011, technology that he now is using to demonstrate a way to provide more protection against SARS and COVID-19.

Curran, who often says he hates to "play defense," hopes to get a jump on the virus spread with his new technology and take a proactive approach to a long-term issue. "Remember, H1N1 affected 61 million Americans and 12,500 people died from it between 2009 and 2010," he notes. "Do we think that's it? Did we think Ike was the last big hurricane to hit us, or do we expect more? Yet, we have compensated for this and found a way to be resilient and have a normal life."

Technical and scientific in his work, the passionate professor says he is galvanized by a simple, primal motive. "This is personal, this virus has threatened my family and I'm not sitting back, ideally, just letting this happen," Curran says. "I'm just like any other husband, father, son, brother, and uncle: I will do all I can to protect those dearest to me and I will not have it any other way."

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

CPRIT CEO: Houston’s $2B in funding is transforming cancer research and prevention

fighting cancer

With its plethora of prestigious health care organizations like the University of Texas MD Anderson Cancer Center, UTHealth Houston, and the Baylor College of Medicine, Houston sits at the heart of cancer research and prevention in Texas.

Of course, it takes piles of cash to support Houston’s status as the state’s hub for cancer research and prevention. Much of that money comes from the Cancer Prevention and Research Institute of Texas (CPRIT).

Data supplied by CPRIT shows organizations in Harris County gained $2.3 billion in institute funding from 2009 through 2025, or nearly $145 million per year. That represents almost 60 percent of the roughly $4 billion that CPRIT has granted to Texas institutions over a 16-year period.

“The life sciences ecosystem that has developed and changed in Houston is phenomenal,” Kristen Doyle, who became the agency’s CEO in July 2024, tells InnovationMap. “In the next decade, we will look back and see a great transformation.”

That ecosystem includes more than 1,100 life sciences and biotech companies, according to the Greater Houston Partnership.

Houston plays critical role in clinical trials

Texas voters approved the creation of CPRIT in 2007. Twelve years later, voters agreed to earmark an extra $3 billion for CPRIT, bringing the state agency’s total investment in cancer research and prevention to $6 billion.

To date, CPRIT money has gone toward recruiting 344 cancer researchers to Texas (mainly to Houston) and has supported cancer prevention services for millions of Texans in the state’s 254 counties. CPRIT funding has also helped establish, expand, or relocate 25 cancer-focused companies. In Houston, MD Anderson ranks as the No. 1 recipient of CPRIT funding.

Regarding cancer research, Doyle says Houston plays a critical role in clinical trials.

“[Clinical trials are] something that CPRIT has focused on more and more. Brilliant discoveries are crucial to this whole equation of solving the cancer problem,” Doyle says. “But if those brilliant ideas stay in the labs, then we’ve all failed.”

Researchers conduct more clinical trials in Houston than anywhere else in the U.S., the Greater Houston Partnership says.

Doyle, a 20-year survivor of leukemia, notes that a minority of eligible patients participate in clinical trials for cancer treatments, “and that’s one of the reasons that it takes so long to get a promising drug to market.”

An estimated 7 percent of cancer patients sign up for clinical trials, according to a study published in 2024 in the Journal of Clinical Oncology.

MD Anderson takes on cancer prevention

Doyle also notes that Houston is leading the charge in cancer prevention.

“We get some national recognition for programs that have been developed in Houston that then can be replicated in other parts of the country,” she says.

Much of the work in Houston focusing on cancer prevention takes place at MD Anderson. The hospital reports that it has received more than $725 million from the CPRIT since 2007, representing approximately 18 percent of CPRIT’s total awards.

“These efforts can have profound impact on the lives of patients and their families, and this funding ensures our exemplary clinicians and scientists can continue working together to drive breakthroughs that advance our mission to end cancer,” Dr. Giulio Draetta, chief scientific officer at MD Anderson, said in a November news release, following the most recent CPRIT award for the hospital totalling more than $29 million.

CPRIT funding for Houston institutions supplements the more than $4.5 billion in federal funding for health and life sciences research and innovations that the Houston area received from 2020 to 2024, according to the Greater Houston Partnership.

“We are curing cancer every single day,” Doyle says of CPRIT. “Every step that we are taking — whether that’s funding great ideas or funding the clinical trials that are bringing promising drugs to Texas and to the world — we are making a difference.”

Houston energy tech co. breaks ground on low-cost hydrogen pilot plant

Coming Soon

Houston’s Lummus Technology and Advanced Ionics have broken ground on their hydrogen pilot plant at Lummus’ R&D facility in Pasadena, Texas.

The plant will support Advanced Ionics’ cutting-edge electrolyzer technology, which aims to deliver high-efficiency hydrogen production with reduced energy requirements.

“By demonstrating Advanced Ionics’ technology at our state-of-the-art R&D facility, we are leveraging the expertise of our scientists and R&D team, plus our proven track record of developing breakthrough technologies,” Leon de Bruyn, president and CEO of Lummus, said in a news release. “This will help us accelerate commercialization of the technology and deliver scalable, cost-effective and sustainable green hydrogen solutions to our customers.”

Advanced Ionics is a Milwaukee-based low-cost green hydrogen technology provider. Its electrolyzer converts process and waste heat into green hydrogen for less than a dollar per kilogram, according to the company. The platform's users include industrial hydrogen producers looking to optimize sustainability at an affordable cost.

Lummus, a global energy technology company, will operate the Advanced Ionics electrolyzer and manage the balance of plant systems.

In 2024, Lummus and Advanced Ionics established their partnership to help advance the production of cost-effective and sustainable hydrogen technology. Lummus Venture Capital also invested an undisclosed amount into Advanced Ionics at the time.

“Our collaboration with Lummus demonstrates the power of partnerships in driving the energy transition forward,” Ignacio Bincaz, CEO of Advanced Ionics, added in the news release. “Lummus serves as a launchpad for technologies like ours, enabling us to validate performance and integration under real-world conditions. This milestone proves that green hydrogen can be practical and economically viable, and it marks another key step toward commercial deployment.”

---

This article originally appeared on EnergyCapitalHTX.com.

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.